Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132945 · ClinicalTrials.gov registry record · Phase 1
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
A Phase 1 study of Brain Metastases and Metastatic Renal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 7
- Study locations
NCT06132945: Active Phase 1 study of Brain Metastases and Metastatic Renal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06132945 is a Phase 1 study of Brain Metastases and Metastatic Renal Cell Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 2 participants, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06132945, a Phase 1 study of Brain Metastases and Metastatic Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study treatment affects the quality of life of participants. They will measure the quality of life by having participants complete questionnaires.
Primary Outcome
56-day safety monitoring period without unacceptable CNS toxicity. Unacceptable CNS toxicity is defined as any grade ≥3 treatment-emergent neurological disorder, per NCI CTCAE version 5.0 criteria
Conditions Studied
Interventions
- DRUG Cabozantinib
- RADIATION Stereotactic Radiosurgery (SRS)
- DEVICE Nivolumab
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-11-10 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
What the registry record for NCT06132945 still lists
NCT06132945 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Brain Metastases appearing as the primary indexed condition, and to 3 interventions - of which Cabozantinib is the first listed.
NCT06132945 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06132945 about?
NCT06132945 is a clinical study titled "A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain". The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study trea...
What is the current status of trial NCT06132945?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2023-11-10. Estimated completion is 2027-11.
What conditions does trial NCT06132945 study?
This clinical trial studies the following conditions: Brain Metastases, Metastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT06132945?
The interventions under investigation include: Cabozantinib (DRUG), Stereotactic Radiosurgery (SRS) (RADIATION), Nivolumab (DEVICE).
Who is sponsoring clinical trial NCT06132945?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06132945 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06132945's enrollment target sits among peer trials
2 68th of 67 the lowest of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
RECRUITING · Phase 1
-
Phase I Study of Fractionated Stereotactic Radiation Therapy
RECRUITING · Phase 1
-
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI